Literature DB >> 19561589

Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase.

Michel DuPage1, Alison L Dooley, Tyler Jacks.   

Abstract

The development of animal models of lung cancer is critical to our understanding and treatment of the human disease. Conditional mouse models provide new opportunities for testing novel chemopreventatives, therapeutics and screening methods that are not possible with cultured cell lines or xenograft models. This protocol describes how to initiate tumors in two conditional genetic models of human non-small cell lung cancer (NSCLC) using the activation of oncogenic K-ras alone or in combination with the loss of function of p53. We discuss methods for sporadic expression of Cre in the lungs through engineered adenovirus or lentivirus, and provide a detailed protocol for the administration of the virus by intranasal inhalation or intratracheal intubation. The protocol requires 1-5 min per mouse with an additional 30-45 min to set-up and allow for the recovery of mice from anesthesia. Mice may be analyzed for tumor formation and progression starting 2-3 weeks after infection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19561589      PMCID: PMC2757265          DOI: 10.1038/nprot.2009.95

Source DB:  PubMed          Journal:  Nat Protoc        ISSN: 1750-2799            Impact factor:   13.491


  33 in total

1.  Generalized lacZ expression with the ROSA26 Cre reporter strain.

Authors:  P Soriano
Journal:  Nat Genet       Date:  1999-01       Impact factor: 38.330

2.  Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer.

Authors:  J Jonkers; R Meuwissen; H van der Gulden; H Peterse; M van der Valk; A Berns
Journal:  Nat Genet       Date:  2001-12       Impact factor: 38.330

3.  The differential effects of mutant p53 alleles on advanced murine lung cancer.

Authors:  Erica L Jackson; Kenneth P Olive; David A Tuveson; Roderick Bronson; Denise Crowley; Michael Brown; Tyler Jacks
Journal:  Cancer Res       Date:  2005-11-15       Impact factor: 12.701

4.  K-ras is an essential gene in the mouse with partial functional overlap with N-ras.

Authors:  L Johnson; D Greenbaum; K Cichowski; K Mercer; E Murphy; E Schmitt; R T Bronson; H Umanoff; W Edelmann; R Kucherlapati; T Jacks
Journal:  Genes Dev       Date:  1997-10-01       Impact factor: 11.361

5.  Inhibition of influenza virus production in virus-infected mice by RNA interference.

Authors:  Qing Ge; Lily Filip; Ailin Bai; Tam Nguyen; Herman N Eisen; Jianzhu Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-01       Impact factor: 11.205

6.  Gene transfer and genetic modification of embryonic stem cells by Cre- and Cre-PR-expressing MESV-based retroviral vectors.

Authors:  Stelios Psarras; Niki Karagianni; Christoph Kellendonk; François Tronche; François-Loic Cosset; Carol Stocking; Volker Schirrmacher; Harald von Boehmer Hv; Khashayarsha Khazaie
Journal:  J Gene Med       Date:  2004-01       Impact factor: 4.565

7.  Incorporation of adenovirus in calcium phosphate precipitates enhances gene transfer to airway epithelia in vitro and in vivo.

Authors:  A Fasbender; J H Lee; R W Walters; T O Moninger; J Zabner; M J Welsh
Journal:  J Clin Invest       Date:  1998-07-01       Impact factor: 14.808

8.  In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector.

Authors:  L Naldini; U Blömer; P Gallay; D Ory; R Mulligan; F H Gage; I M Verma; D Trono
Journal:  Science       Date:  1996-04-12       Impact factor: 47.728

Review 9.  Maximizing mouse cancer models.

Authors:  Kristopher K Frese; David A Tuveson
Journal:  Nat Rev Cancer       Date:  2007-09       Impact factor: 60.716

10.  Suppression of non-small cell lung tumor development by the let-7 microRNA family.

Authors:  Madhu S Kumar; Stefan J Erkeland; Ryan E Pester; Cindy Y Chen; Margaret S Ebert; Phillip A Sharp; Tyler Jacks
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-28       Impact factor: 11.205

View more
  393 in total

1.  Translating cancer 'omics' to improved outcomes.

Authors:  Emily A Vucic; Kelsie L Thu; Keith Robison; Leszek A Rybaczyk; Raj Chari; Carlos E Alvarez; Wan L Lam
Journal:  Genome Res       Date:  2012-02       Impact factor: 9.043

2.  Origins of tumor-associated macrophages and neutrophils.

Authors:  Virna Cortez-Retamozo; Martin Etzrodt; Andita Newton; Philipp J Rauch; Aleksey Chudnovskiy; Cedric Berger; Russell J H Ryan; Yoshiko Iwamoto; Brett Marinelli; Rostic Gorbatov; Reza Forghani; Tatiana I Novobrantseva; Victor Koteliansky; Jose-Luiz Figueiredo; John W Chen; Daniel G Anderson; Matthias Nahrendorf; Filip K Swirski; Ralph Weissleder; Mikael J Pittet
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-30       Impact factor: 11.205

3.  Predicting therapeutic nanomedicine efficacy using a companion magnetic resonance imaging nanoparticle.

Authors:  Miles A Miller; Suresh Gadde; Christina Pfirschke; Camilla Engblom; Melissa M Sprachman; Rainer H Kohler; Katherine S Yang; Ashley M Laughney; Gregory Wojtkiewicz; Nazila Kamaly; Sushma Bhonagiri; Mikael J Pittet; Omid C Farokhzad; Ralph Weissleder
Journal:  Sci Transl Med       Date:  2015-11-18       Impact factor: 17.956

4.  Quantitative Imaging of Tumor-Associated Macrophages and Their Response to Therapy Using 64Cu-Labeled Macrin.

Authors:  Hye-Yeong Kim; Ran Li; Thomas S C Ng; Gabriel Courties; Christopher Blake Rodell; Mark Prytyskach; Rainer H Kohler; Mikael J Pittet; Matthias Nahrendorf; Ralph Weissleder; Miles A Miller
Journal:  ACS Nano       Date:  2018-12-11       Impact factor: 15.881

Review 5.  Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy.

Authors:  Shivani Srivastava; Stanley R Riddell
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

6.  Contrast agents for quantitative microCT of lung tumors in mice.

Authors:  Kush Lalwani; Anand Giddabasappa; Danan Li; Peter Olson; Brett Simmons; Farbod Shojaei; Todd Van Arsdale; James Christensen; Amy Jackson-Fisher; Anthony Wong; Patrick B Lappin; Jeetendra Eswaraka
Journal:  Comp Med       Date:  2013       Impact factor: 0.982

7.  Role of KEAP1/NRF2 and TP53 Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance.

Authors:  Youngtae Jeong; Ngoc T Hoang; Alexander Lovejoy; Henning Stehr; Aaron M Newman; Andrew J Gentles; William Kong; Diana Truong; Shanique Martin; Aadel Chaudhuri; Diane Heiser; Li Zhou; Carmen Say; Justin N Carter; Susan M Hiniker; Billy W Loo; Robert B West; Philip Beachy; Ash A Alizadeh; Maximilian Diehn
Journal:  Cancer Discov       Date:  2016-09-23       Impact factor: 39.397

8.  Inactivation of SAG/RBX2 E3 ubiquitin ligase suppresses KrasG12D-driven lung tumorigenesis.

Authors:  Hua Li; Mingjia Tan; Lijun Jia; Dongping Wei; Yongchao Zhao; Guoan Chen; Jie Xu; Lili Zhao; Dafydd Thomas; David G Beer; Yi Sun
Journal:  J Clin Invest       Date:  2014-01-16       Impact factor: 14.808

9.  Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor.

Authors:  Camilla L Christensen; Nicholas Kwiatkowski; Brian J Abraham; Julian Carretero; Fatima Al-Shahrour; Tinghu Zhang; Edmond Chipumuro; Grit S Herter-Sprie; Esra A Akbay; Abigail Altabef; Jianming Zhang; Takeshi Shimamura; Marzia Capelletti; Jakob B Reibel; Jillian D Cavanaugh; Peng Gao; Yan Liu; Signe R Michaelsen; Hans S Poulsen; Amir R Aref; David A Barbie; James E Bradner; Rani E George; Nathanael S Gray; Richard A Young; Kwok-Kin Wong
Journal:  Cancer Cell       Date:  2014-12-08       Impact factor: 31.743

10.  Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer.

Authors:  Miriam Molina-Arcas; David C Hancock; Clare Sheridan; Madhu S Kumar; Julian Downward
Journal:  Cancer Discov       Date:  2013-03-01       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.